

Survey Results

Sara Biddle

2023-11-16

There were ten dyads enrolled in this study over the course of three recruitment waves. A dyad consisted of a participant with Parkinson’s Disease and their caregiver (generally their spouse). In one dyad, there was not a participating caregiver. One dyad participated in pretesting but dropped the study before posttesting and is not included in this analysis.

Geriatric Depression Scale (Short Form)

The Geriatric Depression Scale Short Form is a fifteen item questionnaire. Each item has binary answer choices ‘yes’ and ‘no’. Items 1, 5, 7, 11, and 13 are scored 1 point for ‘no’ and 0 points for ‘yes’. Items 2, 3, 4, 6, 8, 9, 10, 12, 14, and 15 are scored 1 point for ‘yes’ and 0 points for ‘no’. Points are totaled and the total is evaluated as follows: a score less than 5 is normal, 5-8 indicates mild depression, 9-11 indicates moderate depression, and a score greater than 12 indicates severe depression.

At Pre-Test, all eight care partners scored in the ‘normal’ category. At Post-Test, all eight care partners scores in the ‘normal’ category. At Pre-Test, six out of nine patients with Parkinson’s Disease scored in the ‘normal’ category and two patients scored in the ‘mild depression’ category (see Table [scoreinterpretations-table]). One patient scored in the ‘severe depression’ category at Pre-Test (see Table [scoreinterpretations-table]). At Post-Test, the patient who scored ‘severe depression’ at Pre-Test scored in the ‘normal’ category at Post-Test. No patients scored in the ‘severe depression’ category at Post-Test. All patients with Parkinson’s Disease who scored in the ‘normal’ category at Pre-Test scored in the ‘normal’ category at Post-Test.

According to a 2019 study, the minimal clinically important difference in the Geriatric Depression Scale (15 Items) for improvement and deterioration were 5 and 4 points respectively (Quinten et al. 2019). The largest change in score among care partners was a decrease of two points. Three care partners had no change in score. One patient with Parkinson’s Disease had a decrease in score of eight points. This patient scored in the ‘severe depression’ category at Pre-Test and scored in the ‘normal’ category at Post-Test and was the only patient to participate in the study without a care partner. None of the other eight patients with Parkinson’s Disease had a change in score greater than two points. Using the minimal clinically important difference cutoffs from the study reported above, one patient with Parkinson’s Disease and no care partners reached minimal clinically important difference in GDS15 scores.

We are 95% confident that the true change in Geriatric Depression Scale scores for patients with Parkinson’s Disease after a tandem cycling intervention is between -3.33 and 0.66 points ($t(8) = -1.54$, $p = 0.16$).

We are 95% confident that the true change in Geriatric Depression Scale scores for care partners after a tandem cycling intervention is between -1.57 and -0.18 points ($t(7) = -2.97$, $p = 0.02$).

Table 1: Participation in Pre and Post Testing

Role	Pre Test	Post Test
Care Partner	8	8
PD Patient	9	9

Table 2: Demographics

	Mean (sd)
Care Partner Gender (n, %)	
Female	5 (62.5%)
Male	3 (37.5%)
PD Patient Gender (n, %)	
Female	4 (44.44%)
Male	5 (55.56%)
Age (years)	
Care Partner	68.5 (7.39)
PD Patient	70.22 (5.8)
Education (years)	
Care Partner	14.57 (2.51)
PD Patient	14.56 (1.94)
PD Patient	
Age of PD Onset	68.78 (5.91)
Hoen & Yahr Score	2.22 (0.36)
Symptom Duration (years)	1.54 (1)
Carbidopa-Levodopa Dose (mg/day)	163.89 (71.93) - 655.56 (287.71)

General Anxiety Disorder - 7

The GAD-7 is a seven item survey, where each item is a Lickert scale with choices ‘Not at all’, ‘Several Days’, ‘More than half the days’, and ‘Nearly every day’, scored as 0, 1, 2, and 3 respectively.

The seven items are totaled and the total score is interpreted as follows: a score less than 5 indicates minimal anxiety, 5-9 indicates mild anxiety, 10 - 14 indicated moderate anxiety, and 15 or greater indicates severe anxiety.

At Pre-Test, six patients scored in the ‘minimal anxiety category’, two patients scored in the ‘mild anxiety’ category, and one patient scored in the ‘moderate anxiety’ category. At Post-Test, five patients scored in the ‘minimal anxiety’ category and four patients scored in the ‘mild anxiety category’. The patient who scored in the ‘moderate anxiety’ category at Pre-Test scored in the ‘minimal anxiety’ category at Post-Test. Three patients who scored in the ‘minimal anxiety’ category at Pre-Test scored in the ‘mild anxiety’ category at Post-Test. One patient who scored in the ‘mild anxiety’ category at Pre-Test scored in the ‘minimal anxiety’ category at Post-Test.

At Pre-Test, seven care partners scored in the ‘minimal anxiety’ category and one care partner scored in the ‘mild anxiety’ category. At Post-Test, all eight care partners scored in the ‘mild anxiety’ category.

The minimal clinically important difference on the GAD-7 is four points (Toussaint et al. 2020).

Using the minimal clinically important difference from the study cited above, one care partner had a clinically important decrease in GAD7 score from Pre-Test to Post-Test. Two Parkinson’s Disease patients had clinically important decreases in GAD7 score from Pre-Test to Post-Test and three Parkinson’s Disease patients had a clinically important increase in GAD7 score from Pre-Test to Post-Test.

We are 95% confident that the true change in General Anxiety Disorder score for patients with Parkinson’s Disease after a tandem cycling intervention is between -3.88 and 4.32 points ($t(8) = 0.12$, $p = 0.9$).

We are 95% confident that the true change in General Anxiety Disorder score for care partners after a tandem cycling intervention is between -2.52 and 1.27 points ($t(7) = -0.78$, $p = 0.46$).

Table 3: Geriatric Depression Scale and General Anxiety Disorder Survey Scores Reported as mean (standard deviation)

Survey	Care Partner			PD Patient		
	Pre-Test	Post-Test	Difference	Pre-Test	Post-Test	Difference
GAD7	1.5 (2.51)	0.88 (1.36)	-0.62 (2.26)	3.44 (4.25)	3.67 (3.64)	0.22 (5.33)
GD	2.62 (1.51)	1.75 (1.16)	-0.88 (0.83)	4.33 (3.87)	3 (2.24)	-1.33 (2.6)

Brief Resilience Scale

The Brief Resilience Scale is a six item survey with answers using a five point Lickert-scale. Items 1, 3, and 5 are positively worded and Items 2, 4, and 6 are negatively worded, therefore Items 2, 4, and 6 are scored by reverse coding the answers. The overall score is determined by taking the mean of the six items.

When interpreting the score, less than 3.00 indicates low resilience, 3.00-4.30 indicates normal resilience, and greater than 4.30 indicates high resilience.

At Pre-Test, six of the Parkinson's Disease Patients scored in the 'normal resilience' category and three scored in the 'high resilience category'. At Post-Test, one patient scored as 'low resilience', 6 patients scored as 'normal resilience', and two patients scored as 'high resilience'. One patient who scored as 'normal resilience' at Pre-Test scored as 'low resilience' at Post-Test, one patient who scored as 'normal resilience' at Pre-Test scored as 'high resilience' at Post-Test, and two patients who scored as 'high resilience' at Pre-Test scored as 'normal resilience' at Post-Test.

At Pre-Test, six care partners scored in the 'normal resilience' category and two care partners scored in the 'high resilience' category. At Post-Test, five care partners scored in the 'normal resilience' category and three care partners scored in the 'high resilience' category. Two care partners who scored in the 'normal resilience' category at Pre-Test scored in the 'high resilience' category at Post-Test and one care partner who scored in the 'high resilience' category at Pre-Test scored in the 'normal resilience' category at Post-Test.

We are 95% confident that the change in Brief Resilience Scale score for care partners after a tandem cycling intervention is between -0.39 and 0.64 points ($t(7) = 0.57$, $p = 0.58$).

We are 95% confident that the change in Brief Resilience Scale score for patients with Parkinson's Disease after a tandem cycling intervention is between -0.45 and 0.38 points ($t(8) = -0.21$, $p = 0.84$).

Revised Dyadic Adjustment Scale

One patient completed the study without a caregiver and thus did not complete this scale.

<https://relationshipinstitute.com.au/uploads/resources/Revised-Dyadic-Adjustment-Scale-RDAS-1.pdf>

The Revised Dyadic Adjustment Scale is a fourteen item survey that measures seven dimensions of a couple's relationship among three greater categories. Each item is a 5 or 6 point Lickert scale. Items are summed and the total score can range from 0-69. Higher scores indicate greater relationship satisfaction and lower scores indicate greater relationship distress. The overall cutoff score is 48 with scores below 48 indicating relationship/marital distress and scores above 48 indicating non-distress.

The Consensus dimension consists of Items 1-6 and measures consensus on matters of importance to marital functioning. The Satisfaction dimension consists of Items 7-10 and measures dyadic satisfaction. The Cohesion dimension consists of Items 11-14 and measures dyadic cohesion.

When reviewing the RDAS, one participant had abnormal responses at post test. These responses indicated that the participant, who had answered the survey at pre-test indicating a very happy marriage, was now considering divorce almost every day and was extremely unhappy in the marriage. These answers were only

Table 4: Score Interpretations of GDS, GAD7, RDAS, MoCA, and BRS. One participant did not complete the study with a care partner and thus is not included in the RDAS data.

Survey	Score Interpretation	Care Partner		PD Patient	
		Pre-test	Post-test	Pre-test	Post-test
GAD-7	Minimal Anxiety	7	8	6	5
	Mild Anxiety	1	0	2	4
	Moderate Anxiety	0	0	1	0
GDS	Normal	8	8	6	7
	Mild Depression	0	0	2	2
	Severe Depression	0	0	1	0
RDAS	Non-Distress	8	7	8	8
	Distress	0	1	0	0
MoCA	Normal	4	5	4	5
	Impaired	4	3	5	4
BRS	Low Resilience	0	0	0	1
	Normal Resilience	6	5	6	6
	High Resilience	2	3	3	2

on the four reverse coded questions (7-10) and the participant’s partner did not indicate any issues in the marriage at post test compared to pre test. After discussion, we decided to look at the data both including and excluding this participant’s data. RDAS scores were not significantly different from pre test to post test whether this participant was included or not. This participant was the only participant that indicated distress in the relationship at post testing.

When using the Revised Dyadic Adjustment scale for longitudinal testing or for studies where the subjects are tested at least twice, the RDA is designed to be able to be split in half and have one question for each subscale for a total of seven questions. The survey can be administered this way with one half for pre-testing and the second half for post-testing, which allows for control over bias from repeat testing. Future research using this scale may benefit from using this process.

PROMIS - 29 Profile v2.0


The PROMIS Adult Profile is a 29 item survey. A score of 50 is considered average for the United States general adult population. A higher score indicates more of the concept being measured. The PROMIS-29 has the following subcategories: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. The items are scored on a four-point Likert scale.

The threshold to evaluate within-group change or to make a between-group comparison generally ranges between 2 and 6 T-score points.

We are 95% confident that the true change in PROMIS-29 Fatigue dimension t-score for patients with Parkinson’s Disease after a tandem cycling intervention lies between -10.88 and -1.1 points ($t(8) = -2.83$, $p = 0.02$).

We are 95% confident that the true change in PROMIS-29 Social Participation dimension t-score for patients with Parkinson’s Disease after a tandem cycling intervention lies between 2.62 and 6.76 points ($t(8) = 5.21$,

p = 0).



PDQ 39

For each dimension of the PDQ-39, the answers are summed across the items and divided by the total possible points on the items answered. This is then multiplied by 100 to obtain the dimension summary index.

Each dimension is scored from 0 to 100, with lower scores reflecting better quality of life, therefore if using change in score calculated as Posttest score minus Pretest score, a negative difference would reflect a decrease in score and therefore an improvement.

The minimum clinically important difference of PDQ-39 summary indices was 4.22 for worsening and -4.72 for improvement (Horváth et al. 2017).

We are 95% confident that the change in PDQ-39 Mobility dimension for patients with Parkinson's Disease after a tandem cycling intervention lies between -23.96 and -3.26 points ($t(8) = -3.03$, $p = 0.02$).

Table 5: Results from T-test of Difference in PROMIS Dimension T-Scores from Pre Test to Post Test by Role


Dimension	Role	Mean Difference	Std.Err.	95% Conf.Int.	p-value	t	df
Anxiety	Care Partner	2.33	1.24	(-0.6, 5.25)	0.10	1.88	7
	PD Patient	-2.89	2.34	(-8.29, 2.51)	0.25	-1.23	8
Depression	Care Partner	-1.35	1.35	(-4.54, 1.84)	0.35	-1.00	7
	PD Patient	-2.19	2.29	(-7.46, 3.08)	0.37	-0.96	8
Fatigue	Care Partner	-0.99	1.73	(-5.07, 3.1)	0.59	-0.57	7
	PD Patient	-5.99	2.12	(-10.88, -1.1)	0.02	-2.83	8
Pain Interference	Care Partner	0.56	2.56	(-5.49, 6.62)	0.83	0.22	7
	PD Patient	-3.12	2.56	(-9.02, 2.77)	0.26	-1.22	8
Physical Function	Care Partner	2.54	1.64	(-1.47, 6.56)	0.17	1.55	6
	PD Patient	1.54	1.44	(-1.78, 4.87)	0.31	1.07	8
Sleep Disturbance	Care Partner	0.95	1.20	(-2.14, 4.04)	0.46	0.79	5
	PD Patient	-0.02	1.69	(-3.93, 3.89)	0.99	-0.01	8
Social Participation	Care Partner	2.10	1.50	(-1.45, 5.65)	0.20	1.40	7
	PD Patient	4.69	0.90	(2.62, 6.76)	0.00	5.21	8

Table 6: PROMIS Subdimension T-Scores by Role for Pre Test, Post Test, and Difference Between Pre and Post Test reported as mean (std. dev.)

Dimension	Care Partner			PD Patient		
	Pre-Test	Post-Test	Difference	Pre-Test	Post-Test	Difference
Anxiety	41.26(2.72)	43.59(4.64)	2.33(3.5)	51.22(9.97)	48.33(8.59)	-2.89(7.02)
Depression	42.35(3.82)	41(0)	-1.35(3.82)	48.94(8.77)	46.76(7.67)	-2.19(6.86)
Fatigue	49.2(7.99)	48.21(8.73)	-0.99(4.89)	54.73(8.24)	48.74(9.35)	-5.99(6.36)
Pain Interference	45.46(7.19)	46.02(9.08)	0.56(7.24)	55.8(6.81)	52.68(7.93)	-3.12(7.67)
Physical Function	51.43(5.21)	51.52(8.36)	2.54(4.34)	44.13(6.87)	45.68(6.02)	1.54(4.32)
Sleep Disturbance	49.05(2.13)	49.33(3.38)	0.95(2.94)	52.16(5.95)	52.13(3.04)	-0.02(5.08)
Social Participation	56.52(7.29)	58.62(6.89)	2.1(4.25)	48.37(8.02)	53.06(8.43)	4.69(2.7)

Table 7: Results from Paired T-Test of Change in PDQ-39 dimensions From Pre-Test to Post-Test

Dimension	Mean Difference	Std.Err.	95% Conf. Int	p-value	t	df
Activities of Daily Living	-1.39	3.26	(-8.9, 6.12)	0.68	-0.43	8
Bodily Discomfort	-1.85	5.52	(-14.57, 10.87)	0.75	-0.34	8
Cognition	-7.64	4.51	(-18.05, 2.77)	0.13	-1.69	8
Communication	-4.63	5.57	(-17.49, 8.23)	0.43	-0.83	8
Emotional Well Being	-8.33	6.86	(-24.57, 7.9)	0.26	-1.21	7
Mobility	-13.61	4.49	(-23.96, -3.26)	0.02	-3.03	8
Social Support	-5.56	2.78	(-11.96, 0.85)	0.08	-2.00	8
Stigma	3.47	5.22	(-8.56, 15.51)	0.52	0.67	8
Summary Index	-4.71	3.93	(-14.02, 4.59)	0.27	-1.20	7



MoCA

The Montreal Cognitive Assessment (MoCA) was administered at pre-test and post-test for all participants. The MoCA has a total score between 0 and 30, with a score of 26 or higher considered ‘normal cognitive function’. A study of cognitive function after a subarachnoid hemorrhage caused by cerebral aneurysm determined that a minimum clinically important difference in MoCA score associated with a change of health in general was 2 points (Wong et al. 2017).

Table 8: PDQ39 dimension scores by Role for Pre Test, Post Test, and Difference Between Pre and Post Test reported as mean (std. dev.)

Dimension	Pre-Test	Post-Test	Difference
Activities of Daily Living	17.59(16.51)	16.2(15.23)	-1.39(9.77)
Bodily Discomfort	34.26(20.6)	32.41(23.73)	-1.85(16.55)
Cognition	28.47(22.12)	20.83(17.95)	-7.64(13.54)
Communication	14.81(17.57)	10.19(17.07)	-4.63(16.72)
Emotional Well Being	22.4(22.26)	12.5(19.32)	-8.33(19.42)
Mobility	34.44(25.18)	20.83(23.55)	-13.61(13.47)
Social Support	8.33(10.21)	2.78(4.17)	-5.56(8.33)
Stigma	8.33(15.62)	11.81(16.96)	3.47(15.66)
Summary Index	21.63(16.12)	15.94(16.01)	-4.71(11.13)

References

- Horváth, Krisztina, Zsuzsanna Aschermann, Márton Kovács, Attila Makkos, Márk Harmat, József Janszky, Sámuel Komoly, Kázmér Karádi, and Norbert Kovács. 2017. “Changes in Quality of Life in Parkinson’s Disease: How Large Must They Be to Be Relevant?” *Neuroepidemiology* 48 (1-2): 1–8. <https://doi.org/10.1159/000455863>.
- Quinten, C., C. Kenis, L. Decoster, P. R. Debruyne, I. De Groof, C. Focan, F. Cornelis, et al. 2019. “Determining Clinically Important Differences in Health-Related Quality of Life in Older Patients with Cancer Undergoing Chemotherapy or Surgery.” *Quality of Life Research* 28: 663–76. <https://doi.org/10.1007/s11136-018-2062-6>.
- Toussaint, Anne, Paul Hüsing, Antje Gumz, Katja Wingenfeld, Martin Härter, Elisabeth Schramm, and Bernd Löwe. 2020. “Sensitivity to Change and Minimal Clinically Important Difference of the 7-Item Generalized Anxiety Disorder Questionnaire (GAD-7).” *Journal of Affective Disorders* 265: 395–401. <https://doi.org/10.1016/j.jad.2020.01.032>.
- Wong, George Kwok Chu, Jodhy Suk Ying Mak, Adrian Wong, Vera Zhi Yuan Zheng, Wai Sang Poon, Jill Abrigo, and Vincent Chung Tong Mok. 2017. “Minimum Clinically Important Difference of Montreal Cognitive Assessment in Aneurysmal Subarachnoid Hemorrhage Patients.” *Journal of Clinical Neuroscience* 46: 41–44. <https://doi.org/10.1016/j.jocn.2017.08.039>.